| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Section on Clinical Pharmacology, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London; and 2Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Submitted 16 March 2004 ; accepted in final form 14 September 2004
We investigated the effects of prostacyclin analogs and isoform-selective phosphodiesterase (PDE) inhibitors, alone and in combination, on pulmonary vascular remodeling in vitro and in vivo. Vascular smooth muscle cells (VSMC) isolated from pulmonary (proximal and distal) and systemic circulations demonstrated subtle variations in expression of PDE isoform mRNA. However, using biochemical assays, we found PDE3 and PDE4 isoforms to be responsible for the majority of cAMP hydrolysis in all VSMC. In growth assays, the prostacyclin analogs cicaprost and iloprost inhibited mitogen-induced proliferation of VSMC in a cAMP-dependent manner. In addition, isoform-selective antagonists of PDEs 1, 3, or 4 inhibited VSMC proliferation, an effect that synergized with the effect of prostacyclin analogs. The inhibitory effects were greater in cells isolated from pulmonary circulation. In an in situ perfused rat lung preparation, administration of prostacyclin analogs or the PDE inhibitors vinpocetine (PDE1), cilostamide (PDE3), or rolipram (PDE4), but not EHNA (PDE2), attenuated acute hypoxic vasoconstriction (HPV). Combinations of agents led to a greater reduction in HPV. Furthermore, during exposure to hypoxia for 13 days, Wistar rats were treated with iloprost, rolipram, cilostamide, or combinations of these agents. Compared with normoxic controls, hypoxic animals developed pulmonary hypertension and distal pulmonary artery muscularization. These parameters were attenuated by iloprost+cilostamide, iloprost+rolipram, and cilostamide+rolipram but were not significantly affected by single agents. Together, these findings provide a greater understanding of the role of cAMP PDEs in VSMC proliferation and provide rationale for combined use of prostacylcin analogs plus PDE3/4 inhibitors in treatment of pulmonary vascular remodeling.
smooth muscle cells; cyclic nucleotides; heterogeneity
This article has been cited by other articles:
|
|
 |
|
  M. C. Ortiz-Capisano, T.-D. Liao, P. A. Ortiz, and W. H. Beierwaltes Calcium-dependent phosphodiesterase 1C inhibits renin release from isolated juxtaglomerular cells Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1469 - R1476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Izikki, B. Raffestin, J. Klar, A. Hatzelmann, D. Marx, H. Tenor, P. Zadigue, S. Adnot, and S. Eddahibi Effects of Roflumilast, a Phosphodiesterase-4 Inhibitor, on Hypoxia- and Monocrotaline-Induced Pulmonary Hypertension in Rats J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 54 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Adderley, E. A. Dufaux, M. Sridharan, E. A. Bowles, M. S. Hanson, A. H. Stephenson, M. L. Ellsworth, and R. S. Sprague Iloprost- and isoproterenol-induced increases in cAMP are regulated by different phosphodiesterases in erythrocytes of both rabbits and humans Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1617 - H1624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Long, A. Crosby, X. Yang, M. Southwood, P. D. Upton, D.-K. Kim, and N. W. Morrell Altered Bone Morphogenetic Protein and Transforming Growth Factor-{beta} Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease Circulation, February 3, 2009; 119(4): 566 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Hanson, A. H. Stephenson, E. A. Bowles, M. Sridharan, S. Adderley, and R. S. Sprague Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H786 - H793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur. Respir. J., July 1, 2008; 32(1): 198 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Huang and M. Peters-Golden Eicosanoid Lipid Mediators in Fibrotic Lung Diseases: Ready for Prime Time? Chest, June 1, 2008; 133(6): 1442 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice FASEB J, June 1, 2008; 22(6): 1849 - 1860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Bauer, T. M. Moore, and I. F. McMurtry Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L580 - L582. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ito, T. Okada, J. Mimuro, H. Miyashita, R. Uchibori, M. Urabe, H. Mizukami, A. Kume, M. Takahashi, U. Ikeda, et al. Adenoassociated Virus Mediated Prostacyclin Synthase Expression Prevents Pulmonary Arterial Hypertension in Rats Hypertension, September 1, 2007; 50(3): 531 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Murray, H. H. Patel, R. Y. S. Suda, S. Zhang, P. A. Thistlethwaite, J. X.-J. Yuan, and P. A. Insel Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1 Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L294 - L303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Said Mediators and modulators of pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kim, K.S. Prabhu, F. J. Gonzalez, and J. M. Peters Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-{beta}/{delta} (PPAR{beta}/{delta}) Carcinogenesis, May 1, 2006; 27(5): 1105 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Busch, H. Liu, A. R. Graveline, and K. D. Bloch Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L747 - L753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. V. Evgenov, C. J. Busch, N. V. Evgenov, R. Liu, B. Petersen, G. E. Falkowski, B. Petho, A. Vas, K. D. Bloch, W. M. Zapol, et al. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L723 - L729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper and L. J. Rubin Update in pulmonary hypertension 2005. Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 499 - 505. [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Tsai, M. W. Turrentine, B. C. Sheridan, M. Wang, A. C. Fiore, J. W. Brown, and D. R. Meldrum Differential Effects of Phosphodiesterase-5 Inhibitors on Hypoxic Pulmonary Vasoconstriction and Pulmonary Artery Cytokine Expression Ann. Thorac. Surg., January 1, 2006; 81(1): 272 - 278. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
